Business Context and Reporting Period
Company: Electromed, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2010
Business Overview: Electromed develops, manufactures, and markets airway clearance products utilizing High Frequency Chest Wall Oscillation (HFCWO) therapy, primarily the SmartVest® system. The company serves home health care and institutional markets in the U.S. and internationally.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2010 |
|---|---|---|
| Net Revenues | $4,685,546 | $8,850,975 |
| Gross Profit | $3,540,155 (75.6% margin) | $6,473,883 (73.1% margin) |
| Operating Income | $543,037 | $790,795 |
| Net Income (Attributable to Electromed) | $291,872 | $403,943 |
| Earnings Per Share (Diluted) | $0.04 | $0.05 |
| Cash and Cash Equivalents | $5,161,270 (as of Dec 31, 2010) | |
| Total Debt (Current + Long-term) | $3,508,757 (as of Dec 31, 2010) | |
| Working Capital | $11,682,009 (Current Assets $15.3M - Current Liab. $3.6M) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 45.4% for the three months and 37.2% for the six months compared to the prior year periods. This was driven by a 22.9% increase in patient referrals and a 43.4% increase in sales staff (FTEs).
- Profitability: Net income attributable to Electromed surged 727% for the three-month period ($291,872 vs. $35,294) and increased 8.6% for the six-month period ($403,943 vs. $371,029).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 43.7% (three months) and 44.0% (six months) due to increased payroll, health insurance, travel, and marketing costs associated with sales force expansion. R&D expenses increased 61.0% (three months) and 66.1% (six months).
- Cash Flow: Operating cash flow turned negative, using $235,934 for the six months ended Dec 31, 2010, compared to providing $78,319 in the prior year. This was primarily due to a $1.27M increase in accounts receivable and inventory buildup. However, financing activities provided $5.64M, largely from the IPO.
- Capital Structure: The company completed an IPO in August 2010, selling 1.9 million shares for net proceeds of approximately $5.95M. This significantly increased cash reserves and stockholders' equity.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash and credit facilities are sufficient for the next 12 months. They plan to increase R&D expenses to approximately 5% or greater of revenue in the future.
- Margin Commentary: While gross margins improved to 75.6% in the quarter, management does not believe this is indicative of a long-term trend, citing fluctuations in reimbursement yields and insurance program mixes.
- Legal Proceedings: A trademark infringement lawsuit with Hill-Rom regarding the "SmartVest" mark was settled on September 30, 2010. The settlement terms are confidential, but the company retains the right to use its marks. Approximately $1.16M in legal defense costs were capitalized.
- Risks: Key risks include changes in Medicare/Medicaid reimbursement policies, competition, the need for regulatory approvals, and the impact of tight credit markets on financing.
Investor Verification Checklist
- Reimbursement Rates: Verify the sustainability of the 75.6% gross margin, as management attributes the increase to temporary reimbursement mix factors.
- Accounts Receivable: Review the $1.27M increase in accounts receivable and the allowance for doubtful accounts ($45,000) to assess collection risks.
- Debt Covenants: Confirm compliance with financial covenants (fixed charge and cash flow leverage ratios) under the U.S. Bank credit facility.
- Operating Cash Flow: Monitor the trend of negative operating cash flow as the company scales its sales force and inventory levels.
- Related Party Transactions: Note the $180,000 in R&D expenses paid to a related-party service provider owned in part by the CEO and board members.